On Thursday Syndax Pharmaceuticals (NASDAQ:SNDX) stock fell -0.43% and closed at 6.96. The stock opened the session at $7.06 and touched its highest price point at $7.18. Its recent trading capacity is 76844 shares versus to its average trading volume of 179647 shares. The company’s stock’s lowest price point for the session stood at $6.96. SNDX traded as low as $ 3.39 in the past 52 weeks, and shares hit its peak level to $11.11.
On Nov. 7, 2019, Syndax Pharmaceuticals (NASDAQ:SNDX) a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, revealed its financial results for the third quarter ended September 30, 2019. In addition, the Company provided a clinical and business update. As of September 30, 2019, Syndax had $72.2 million in cash, cash equivalents and short-term investments.
We are pleased to have passed the final interim futility analysis of overall survival for E2112, our Phase 3 registration trial of entinostat plus exemestane in HR+, HER2- breast cancer, and anticipate the final overall survival readout in the second quarter of 2020, said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. Supported by highly compelling survival data from the Phase 2b ENCORE 301 trial, leading to Breakthrough Therapy designation for entinostat in HR+ breast cancer, we believe the combination of entinostat and exemestane has the potential to improve outcomes for patients with this difficult to treat disease.
Pending a positive overall survival (OS) assessment in E2112, Syndax intends to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for entinostat plus exemestane for the treatment of HR+, HER2- breast cancer.